C. Th. Smit-Sibinga – författare

Proceedings of the Twenty-Eighth International Symposium on Blood Transfusion, Groningen, NL, Organized by the Sanquin Division Blood Bank North-East, Groningen.It is in many ways fitting that the last of these international symposia on blood transfusion should end with neonatal blood transfusion. The most fragile, least well studied and most at risk population requires special care and concern. We need to expand our knowledge of their unique physiology, biochemical pathways and in planning treatment and interventions, always "do no harm." This proceedings of the last Groningen symposium presents a wealth of information on developmental immunology, the molecular basis of haematopoeisis, physiological basis of bleeding and thrombosis, transfusion risks and benefits and lastly, future therapies. Infants provide us with much to learn but in turn they will be the providers of (through cord blood) and the recipients of (through cellular engineering) the best that science can offer. Translational research, which has been the thrust of these presentations for 28 years, will benefit them in a way that no scientist could have ever predicted.

In transfusion medicine the scientific fundamentals of immunology have had a considerable clinical impact. Transfusion may suppress the immunity but some patients could suffer disadvantages including GvHD, alloimmunisation and possible cancer, where white cells (WBC) play pivotal roles in this phenomenon, presenting antigens and producing cytokines. A clinical application of this practice is LAK-cells targeted against cancer. MHC on the WBC may provide additional immunological modulations through series of secondary messengers. Thus reduction of WBC in the blood and bone marrow may be advantageous for patients. On the other hand, sharing a part of MHC or making the transplanted white cells anergic by storage may be even more advantageous for patients. CMV infection could mimic part of this MHC. UV radiation is effective in the inactivation of the WBC although filters are easy means for such removal. However, their accurate quantification requires flow cytometry that has considerable potential application in blood transfusions. Idiotypic antibody could play an important role in platelet theory.However, the potential infection risks in transfusion like HIV and HCV remain, but application of molecular biological methods like PCR or RT/PCR has great potentials in detection of infectious diseases, transplantation and genetic disorders. Immuno affinity purified concentrates, like factor IX and protein C, could reduce patients' immune functions, where in the future protein C could be derived from transgenic animals. Advances are sure to emerge through adoptive immunotherapy, and gene therapies are exciting prospects when genes transferred into lymphocytes could be used to correct cell mediated immune deficiency, as in ADA.

Transfusion medicine provides an excellent bridge connecting the healthy community donors with the patient's needs at the bedside; the dominant philosophy has been on patient care and science, but it is now realised that blood banks manufacture increasing amounts of blood components to administer to patients - a role analogous to manufacturing functions. The concept of Good Manufacturing Practice (GMP) is therefore relatively new. While quality has always been important, the impact of GMP, Total Quality Management (TQM) and Quality Assurance (QA) will be profound. This publication addresses the various implications of the implementation of these concepts upon transfusion medicine. As the regulatory agencies, like the FDA in the U.S.A. and the EEC Commission in Europe, increase their enforcement activities, doctors, technical experts and managers will have to face many issues of quality assurance including documentation, validation, audit system, regulatory laws, licensing, teaching and training of staff and their job descriptions, standards, processing facilities, procedure validations, automation, record keeping, internal and external quality control of products and their release.The expansion of this philosophy to include Good Clinical Practice (GCP) is an even greater challenge demanding consensus therapy protocols and quality management of transfusion through auditing by the hospital transfusion committees. Such comprehensive plans will profoundly affect the financial and organizational structure of blood transfusion in the future.

Cytokines are cellular growth factors which also provide communication between cells and their milieu. This is an area in modern medicine that should have significant impact on various facets of transfusion. Erythropoietin therapy stimulates red cell production while thrombopoietin seems to positively affect megakaryopoiesis and can be an added armamentarium for the thrombocytopenic patient. Using haemopoietic growth factors, stem cells could be mobilized early to the peripheral blood for collection and subsequent transplantation into haemato-oncology patients instead of bone marrow transplantation. Using a cocktail of cytokines in cell culture, stem cells could be expanded and selected for therapy. Cytokines and growth factors can even be modified, which may lead to successful gene therapy in malignancies, including solid tumour vaccines. However, the presence of cytokines in certain blood products could have biological affects following transfusion, although its clinical relevance needs to be ascertained. There is much potential for the use of cytokines in the treatment of infections. Early diagnostic methods are now available to monitor their levels and relevance.It is likely that cytokines will increasingly play a role in therapy and could develop our fundamental knowledge about the development of T-cells. An ethical dilemma remains, however, regarding the use of cytokines in healthy donors for harvesting suitable specific cells. Longer clinical observation will be necessary to gather the necessary information. Cytokines and growth factors in blood transfusion was the theme of the 21st International Symposium in Blood Transfusion, where 20 clinicians and scientists, experts in their own fields, were invited to update the above information. Their findings are presented in four sections in this volume: 1. Fundamental aspects - cytokines in development of T-cells, growth factors in haematopoiesis, growth factor receptors and signal transduction, cytokine response in platelet and whole blood transfusions. 2. Function, production and diagnosis - laboratory diagnostics of cytokines and growth factors, cytokines in blood components, cytokines and growth factors in cell expansions, cytokines for genetic modification towards gene therapy, progenitor cells from healthy donors. 3.Application in clinical medicine - clinical relevance of cytokines in transfusion products, cytokines and growth factors in solid tumours, gene therapy in malignancies, vaccine strategies inducing T-cell immunity against tumours, cytokines in the treatment of infections, thrombopoietin and megakaryopoiesis. 4. Future potential use in transfusion medicine - erythropoietin, immunotherapy, ethical aspects of the use of cytokines and growth factors in donors, potential of cytokines and growth factors in transfusion medicine.

As appropriately outlined in the first chapter in cells was pioneered in Holland by Van Loghem and part II in this book, the history of contemporary Van Rood, and it led eventually to the discovery of blood transfusion is only three-quarters of a cen- the HLA system and its subsequent explosive de- tury old. On the surface, there is not much left in velopment. In biochemistry, the work on the ABO common between an arm to arm blood transfer and MN blood group substances has provided carried out as an heroic measure in the twenties, pointers to general features of the biosynthesis and when patient or donor had to be weighed in order role of glycolipids and glycoproteins in the cell for the physician to decide when to stop, and blood membrane, and the identification of serological component therapy of today, when several patients specificities associated with specific oligo sac- can benefit from appropriately measured and stan- chari des has proven for the first time how gene dardized amounts of various purified blood frac- products that are not proteins can exhibit Men- tions. Yet, the basic principles of blood transfusion delian inheritance.

This work discusses all aspects of transfusion of transmissible diseases, both the facts and the fiction. Session I addresses the basic blood safety aspects including the need for quality management, rational donor screening and the risks of blood transfusion for prenatal developmental toxicity. Session II addresses the gamma of transmissible infectious agents from bacteria through parasites and tick-borne agents to prions and the risks associated with xeno-transplantation and xenozoonoses. Session III sheds new light on NAT technology for detection of viral DNA and RNA, the cost-effectiveness of the alternatives to allogeneic blood transfusion. To what extent are genetic defects in stem cell genomic structures transmissible through transplantation and does questioning potential donors make any sense? Session IV addresses the preventive aspects on the future of transfusion medicine. Quantitative real-time PCR for Parvo B19 and advances in bacterial detection technology. The advancement from theory to practice of pathogen inactivation technology based on destruction of nucleic acids in cellular structures.Finally, a plea is made for co-operation and collaboration on a global scale, changing the pars pro toto phenomenon (the ships that pass in the night) for a totum pro parte, a true joining of forces to create a global network for blood safety and structured blood supply systems.

Proceedings of the Twenty-Eighth International Symposium on Blood Transfusion, Groningen, NL, Organized by the Sanquin Division Blood Bank North-East, Groningen.It is in many ways fitting that the last of these international symposia on blood transfusion should end with neonatal blood transfusion. The most fragile, least well studied and most at risk population requires special care and concern. We need to expand our knowledge of their unique physiology, biochemical pathways and in planning treatment and interventions, always "do no harm." This proceedings of the last Groningen symposium presents a wealth of information on developmental immunology, the molecular basis of haematopoeisis, physiological basis of bleeding and thrombosis, transfusion risks and benefits and lastly, future therapies. Infants provide us with much to learn but in turn they will be the providers of (through cord blood) and the recipients of (through cellular engineering) the best that science can offer. Translational research, which has been the thrust of these presentations for 28 years, will benefit them in a way that no scientist could have ever predicted.

As appropriately outlined in the first chapter in cells was pioneered in Holland by Van Loghem and part II in this book, the history of contemporary Van Rood, and it led eventually to the discovery of blood transfusion is only three-quarters of a cen- the HLA system and its subsequent explosive de- tury old. On the surface, there is not much left in velopment. In biochemistry, the work on the ABO common between an arm to arm blood transfer and MN blood group substances has provided carried out as an heroic measure in the twenties, pointers to general features of the biosynthesis and when patient or donor had to be weighed in order role of glycolipids and glycoproteins in the cell for the physician to decide when to stop, and blood membrane, and the identification of serological component therapy of today, when several patients specificities associated with specific oligo sac- can benefit from appropriately measured and stan- chari des has proven for the first time how gene dardized amounts of various purified blood frac- products that are not proteins can exhibit Men- tions. Yet, the basic principles of blood transfusion delian inheritance.